ScreenerHero

MGX Metagenomi Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · metagenomi.co
0.9847USD-4.40%Mkt Cap: 37.20M $P/E: —

Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long prote…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap37.20M USD
Enterprise Value-44.03M USD
Revenue (TTM)13.56M USD
Gross Profit-75.03M USD
Net Income (TTM)-87.87M USD
Revenue/Share0.36 USD
Last Price0.9847 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees113
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.56
PEG—
EV/EBITDA0.46
EV/Revenue-3.25
P/S2.87
P/B0.35
EPS (TTM)-2.44
EPS (Forward)-1.83
52W Range
0.96001% of range3.950
52W High3.950 USD
52W Low0.9600 USD
Profitability
Gross Margin0.00%
Oper. Margin11195.72%
EBITDA Margin0.00%
Profit Margin-348.54%
ROE-55.40%
ROA-39.74%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-88.89M USD
CapEx (TTM)574.00K USD
FCF Margin-375.72%
FCF Yield-136.97%
Net Debt-82.94M USD
Net Debt/EBITDA0.87
Balance Sheet
Debt/Equity0.26
Current Ratio4.50
Quick Ratio4.40
Book Value/Sh2.98 USD
Cash/Share3.19 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)7.000 USD
Upside (mean)+610.9%
Target Range5.000 USD – 9.000 USD
5.000+610.9% to mean9.000
# Analysts3
Ownership
Shares Out.37.78M
Float25.54M
Insiders19.02%
Institutions18.72%
Short Interest
Short Ratio8.7d
Short % Float4.67%
Short % Out.3.79%
Shares Short1.43M
Short (prev mo.)1.45M
Technical
SMA 501.176 (-16.3%)
SMA 2001.373 (-28.3%)
Beta0.70
S&P 52W Chg16.45%
Avg Vol (30d)161.14K
Avg Vol (10d)129.13K
Technical Indicators
RSI (14)29.9
MACD-0.0440
MACD Signal-0.0318
MACD Hist.-0.0122
BB Upper1.228 USD
BB Middle1.114 USD
BB Lower1.000 USD
BB Width20.40%
ATR (14)0.0522 USD
Vol Ratio (20d)1.85x